AR096709A1 - Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) - Google Patents
Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)Info
- Publication number
- AR096709A1 AR096709A1 ARP140102374A ARP140102374A AR096709A1 AR 096709 A1 AR096709 A1 AR 096709A1 AR P140102374 A ARP140102374 A AR P140102374A AR P140102374 A ARP140102374 A AR P140102374A AR 096709 A1 AR096709 A1 AR 096709A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- aromatic
- nr8r9
- heterocyclyl
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 16
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 239000003446 ligand Substances 0.000 abstract 3
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente se refiere al uso de un ligando sigma, particularmente un ligando sigma de fórmula (1) para prevenir y/o tratar dolor asociado a cistitis intersticial / síndrome de dolor vesical (CI / SDV). Reivindicación 4: Ligando sigma según una cualquiera de las reivindicaciones 1 a 3, que tiene la fórmula general (1), en la que R se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R² se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R³ y R⁴ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno, o junto con el fenilo forman un sistema de anillos condensados opcionalmente sustituido; R⁵ y R⁶ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno, o juntos forman, con el átomo de nitrógeno al que están unidos, un grupo heterociclilo sustituido o no sustituido, aromático o no aromático; n se selecciona de 1, 2, 3, 4, 5, 6, 7 y 8; t es 0, 1 ó 2; R⁸ y R⁹ se seleccionan cada uno independientemente de hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, alcoxilo sustituido o no sustituido, ariloxilo sustituido o no sustituido y halógeno; o una sal, isómero, profármaco o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382246.0A EP2818166A1 (en) | 2013-06-26 | 2013-06-26 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096709A1 true AR096709A1 (es) | 2016-01-27 |
Family
ID=48700506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102374A AR096709A1 (es) | 2013-06-26 | 2014-06-24 | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) |
Country Status (19)
Country | Link |
---|---|
US (1) | US20160151377A1 (es) |
EP (2) | EP2818166A1 (es) |
JP (1) | JP2016523276A (es) |
KR (1) | KR20160023839A (es) |
CN (1) | CN105377257A (es) |
AR (1) | AR096709A1 (es) |
AU (1) | AU2014301220A1 (es) |
BR (1) | BR112015032343A8 (es) |
CA (1) | CA2916568A1 (es) |
HK (1) | HK1221656A1 (es) |
IL (1) | IL243362A0 (es) |
MA (1) | MA38711A1 (es) |
MX (1) | MX2015017761A (es) |
PH (1) | PH12015502815A1 (es) |
RU (1) | RU2016102149A (es) |
SG (1) | SG11201510408XA (es) |
TN (1) | TN2015000558A1 (es) |
TW (1) | TWI629984B (es) |
WO (1) | WO2014207024A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
MA39146A1 (fr) * | 2013-12-17 | 2017-11-30 | Esteve Labor Dr | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma |
TN2016000228A1 (en) | 2013-12-17 | 2017-10-06 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS. |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2359719T3 (es) * | 2001-07-10 | 2011-05-26 | Astellas Pharma Inc. | Composición farmacéutica comprendiendo quinuclidin-3'-il 1-fenil-1,2,3,4-tetrahidroisoquinolin-2-carboxilato para el tratamiento de la cistitis instersticial y/o la prostatitis no bacteriana. |
EP1781618B1 (en) | 2004-08-27 | 2012-10-03 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
TWI356699B (en) * | 2004-11-10 | 2012-01-21 | Kissei Pharmaceutical | Agent for treating interstitial cystitis and agent |
WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
CN101395157A (zh) * | 2006-03-01 | 2009-03-25 | 伊斯特芬博士实验室有限公司 | 作为西格玛受体抑制剂的吡唑衍生物 |
US8202872B2 (en) * | 2006-03-01 | 2012-06-19 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353598A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2460804A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del Dr. Esteve, S.A. | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics |
EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
JP5933902B2 (ja) * | 2011-05-13 | 2016-06-15 | アレイ バイオファーマ、インコーポレイテッド | Trkaキナーゼ阻害剤としてのピロリジニル尿素およびピロリジニルチオ尿素化合物 |
EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
-
2013
- 2013-06-26 EP EP13382246.0A patent/EP2818166A1/en not_active Withdrawn
-
2014
- 2014-06-24 AR ARP140102374A patent/AR096709A1/es unknown
- 2014-06-24 TW TW103121723A patent/TWI629984B/zh not_active IP Right Cessation
- 2014-06-25 AU AU2014301220A patent/AU2014301220A1/en not_active Abandoned
- 2014-06-25 US US14/900,786 patent/US20160151377A1/en not_active Abandoned
- 2014-06-25 BR BR112015032343A patent/BR112015032343A8/pt not_active Application Discontinuation
- 2014-06-25 SG SG11201510408XA patent/SG11201510408XA/en unknown
- 2014-06-25 MA MA38711A patent/MA38711A1/fr unknown
- 2014-06-25 JP JP2016522457A patent/JP2016523276A/ja active Pending
- 2014-06-25 KR KR1020167001865A patent/KR20160023839A/ko not_active Application Discontinuation
- 2014-06-25 RU RU2016102149A patent/RU2016102149A/ru not_active Application Discontinuation
- 2014-06-25 WO PCT/EP2014/063360 patent/WO2014207024A1/en active Application Filing
- 2014-06-25 EP EP14734099.6A patent/EP3013338A1/en not_active Withdrawn
- 2014-06-25 MX MX2015017761A patent/MX2015017761A/es unknown
- 2014-06-25 CN CN201480040098.1A patent/CN105377257A/zh active Pending
- 2014-06-25 CA CA2916568A patent/CA2916568A1/en not_active Abandoned
- 2014-06-25 TN TN2015000558A patent/TN2015000558A1/en unknown
-
2015
- 2015-12-17 PH PH12015502815A patent/PH12015502815A1/en unknown
- 2015-12-27 IL IL243362A patent/IL243362A0/en unknown
-
2016
- 2016-08-17 HK HK16109869.1A patent/HK1221656A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL243362A0 (en) | 2016-02-29 |
EP3013338A1 (en) | 2016-05-04 |
US20160151377A1 (en) | 2016-06-02 |
TN2015000558A1 (en) | 2017-04-06 |
AU2014301220A1 (en) | 2016-02-18 |
BR112015032343A2 (pt) | 2017-09-26 |
MX2015017761A (es) | 2016-07-06 |
TW201536295A (zh) | 2015-10-01 |
HK1221656A1 (zh) | 2017-06-09 |
RU2016102149A (ru) | 2017-08-02 |
BR112015032343A8 (pt) | 2018-01-23 |
JP2016523276A (ja) | 2016-08-08 |
RU2016102149A3 (es) | 2018-05-25 |
CN105377257A (zh) | 2016-03-02 |
SG11201510408XA (en) | 2016-01-28 |
EP2818166A1 (en) | 2014-12-31 |
WO2014207024A1 (en) | 2014-12-31 |
TWI629984B (zh) | 2018-07-21 |
MA38711A1 (fr) | 2017-12-29 |
PH12015502815A1 (en) | 2016-03-21 |
CA2916568A1 (en) | 2014-12-31 |
KR20160023839A (ko) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) | |
AR101638A1 (es) | Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma | |
AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
AR084730A1 (es) | Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos | |
AR082441A1 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR101637A1 (es) | Combinaciones de gabapentinoides y ligandos de receptores sigma | |
AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
AR086632A1 (es) | Ligandos sigma para la prevencion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
MX2016012984A (es) | Derivados indol para uso en medicina. | |
AR096748A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR098912A1 (es) | Inhibidores de syk | |
AR101177A1 (es) | Inhibidores de la syk | |
AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
AR089175A1 (es) | Inhibidores de pak para el tratamiento de trastornos de proliferacion celular | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |